Comment; Pentadecapeptide BPC 157 appears to be a reasonable replacement for Vasoactive Intestinal Peptide (VIP) in the treatment of chronic inflammatory disorders including central neurologic issues.
Predrag Sikiric,1,*Sven Seiwerth,1Rudolf Rucman,1Danijela Kolenc,1Lovorka Batelja Vuletic,1Domagoj Drmic,1Tihomir Grgic,1Sanja Strbe,1Goran Zukanovic,1Dalibor Crvenkovic,1Goran Madzarac,1Iva Rukavina,1Mario Sucic,1Marko Baric,1Neven Starcevic,1Zoran Krstonijevic,1Martina Lovric Bencic,1Igor Filipcic,1Dinko Stancic Rokotov,1 and Josipa Vlainic2Author informationArticle notesCopyright and License informationDisclaimerThis article has been cited by other articles in PMC.Go to:
Abstract
Background
Brain-gut interaction involves, among others, peptidergic growth factors which are native in GI tract and have strong antiulcer potency and thus could from periphery beneficially affect CNS-disorders. We focused on the stable gastric pentadecapeptide BPC 157, an antiulcer peptidergic agent, safe in inflammatory bowel disease trials and now in multiple sclerosis trial, native and stable in human gastric juice.
Methods
Review of our research on BPC 157 in terms of brain-gut axis.
Results
BPC 157 may serve as a novel mediator of Robert’s cytoprotection, involved in maintaining of GI mucosa integrity, with no toxic effect. BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Stimulated Egr-1 gene, NAB2, FAK-paxillin and JAK-2 pathways are hitherto implicated. Initially corresponding beneficial central influence was seen when BPC 157 was given peripherally and a serotonin release in particular brain areas, mostly nigrostriatal, was changed. BPC 157 modulates serotonergic and dopaminergic systems, beneficially affects various behavioral disturbances that otherwise appeared due to specifically (over)stimulated/damaged neurotransmitters systems. Besides, BPC 157 has neuroprotective effects: protects somatosensory neurons; peripheral nerve regeneration appearent after transection; after traumatic brain injury counteracts the otherwise progressing course, in rat spinal cord compression with tail paralysis, axonal and neuronal necrosis, demyelination, cyst formation and rescues tail function in both short-terms and long-terms; after NSAIDs or insulin overdose or cuprizone encephalopathies were attenuated along with GI, liver and vascular injuries.
Conclusion
BPC 157, a gastric peptide, may serve as remedy in various CNS-disorders.
- COVID UPDATE: What is the truth? - 2022-11-08
- Pathologist Speaks Out About COVID Jab Effects - 2022-07-04
- A Massive Spike in Disability is Most Likely Due to a Wave of Vaccine Injuries - 2022-06-30
